Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development

published 27.07.2020 04:38

Last week, Moderna suffered a setback in its vaccine development as it lost a bid to invalidate a key patent related to the technology for delivery of mRNA vaccines held by Arbutus Biopharma Corp (NASDAQ: ABUS).

Why It Matters Moderna claims it's on track to deliver nearly 500 million doses of the vaccine per year, and it could scale that number up to 1 billion doses next year due to its strategic collaboration with Lonza Group AG (OTC: LZAGY).

What Happened The Cambridge, Massachusetts-based company was originally allocated a $483 billion award, in support of its mRNA-1273 vaccine candidate, as part of its contract with the Biomedical Advanced Research and Development Authority (BARDA).

Moderna Inc. (NASDAQ: MRNA) announced Sunday it is receiving another $472 million funding from President Donald Trump's administration to support late-stage clinical development of its coronavirus vaccine candidate, including an expanded phase 3 study.

Earlier this month, it promised $1.6 billion in funding to Novavax, Inc (NASDAQ: NVAX) for its vaccine’s late-stage trial, reported Politico.

by Shivdeep Dhaliwal from

Free awesomeness straight to your inbox!

Sign up now for this free newsletter to receive hand picked content, covering topics like Lifestyle, Business & Technology.

Free Newsletter Sign up now!

..or jump directly to the latest posts!